Latest Breaking News On - Global therapeutic area head - Page 1 : comparemela.com

Seltorexant for Major Depressive Disorder With Insomnia Symptoms Sees Positive Results

Seltorexant for Major Depressive Disorder With Insomnia Symptoms Sees Positive Results
psychiatrictimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychiatrictimes.com Daily Mail and Mail on Sunday newspapers.

United statesWayne drevetsAndrew krystalBill martinUniversity of californiaAmerican society of clinical psychopharmacologySan francisco weill institute for neurosciencesAmerican college of neuropsychopharmacologyAmerican societyClinical psychopharmacologyAnnual meetingMontgomery asberg depression rating scaleSan francisco weill instituteGlobal therapeutic area headAmerican college

Cidara Therapeutics Provides Corporate Update and Reports

Cidara Therapeutics Provides Corporate Update and Reports
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesDavid gollaherBrian ritchieJeffrey steinLaura tadvalkarTimothy fransonRyan spencerMichael fitzhughJames mersonCompany board of directorsCidara therapeutics incEuropean society of clinical microbiologyJanssen pharmaceuticals incBiotech value fundLifesci communications

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Rockefeller universityNew yorkUnited statesBaden wübergUnited kingdomUniversity of pennsylvaniaCity ofUseh jack bissettSonia quaratinoPureos bioventuresBristol myers squibbIain kiltyJohn davisGerda blobelRussell greigJim hughes

FDA Approves Johnson & Johnson OPSYNVI (macitentan and tadalafil) Single-Tablet Combination for Patients with Pulmonary Arterial Hypertension (PAH)

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension (PAH). The newly-approved drug is a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor.

United statesKelly chinPulmonary hypertension programAmerican lung associationUt southwestern medical centerEuropean respiratory societyEuropean society of cardiologyActelion pharmaceuticals us incDrug administrationWorld health organization groupJournal of the american college cardiologyWorld health organizationInternal medicineMedical centerPulmonary vascular resistanceBoxed warning

FDA Approves Macitentan, Tadalafil Combination Tablet for Pulmonary Arterial Hypertension

The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study.

Kelly chinUt southwestern medical centerPulmonary hypertension programInternal medicineMedical centerBoxed warningMacitentan containing products risk evaluationMitigation strategyGlobal therapeutic area head